Jaclyn Springer
Family · Johnstown, PANPI 1720748825
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,097 of the $14,996 with a category attached, or 67.3%. 38 manufacturers reported payments, led by Boston Scientific at 46.5% of the total. 2025 is the largest year on record at $6,151, 2.0 times the $3,035 reported in 2022. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- AbbVie$1K
- AstraZeneca$994
- Lilly USA, LLC$657
- Novo Nordisk$590
- E.r. Squibb & Sons, L.L.C.$561
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$2,00013%
- Travel & lodging$2,89919%
- Food & beverage$10,09767%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $6,977 |
| AbbVie | 79 | $1,410 |
| AstraZeneca(2 entities) | 25 | $994 |
| Lilly USA, LLC | 46 | $657 |
| Novo Nordisk | 28 | $590 |
| E.r. Squibb & Sons, L.L.C. | 11 | $561 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $430 |
| Exact Sciences | 28 | $406 |
| Pfizer | 23 | $382 |
| Amgen | 18 | $286 |
| Johnson & Johnson | 3 | $195 |
| GSK | 11 | $180 |
| Sanofi-aventis U.S. LLC | 7 | $162 |
| Inari Medical, Inc. | 4 | $160 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Merck | 9 | $143 |
| Phathom Pharmaceuticals, Inc. | 3 | $139 |
| Lundbeck LLC | 7 | $125 |
| Boehringer Ingelheim | 7 | $112 |
| Eisai Inc. | 6 | $111 |
| Bayer | 6 | $105 |
| Verona Pharma, Inc. | 2 | $83 |
| Astellas Pharma US Inc | 3 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Aimmune Therapeutics, Inc. | 4 | $68 |
| Stryker | 2 | $58 |
| Nestle Healthcare Nutrition Inc. | 3 | $55 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Tactile Systems Technology Inc | 1 | $48 |
| Abiomed | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Novartis | 2 | $33 |
| Dexcom, Inc. | 2 | $31 |
| Shield Therapeutics Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$2,889
- WATCHMAN FLX$1,824
- GENERAL - THERAPIES$775
- WATCHMAN Access System$339
- OPDIVO$264
- FARXIGA$250
- QULIPTA$250
- XIFAXAN$125
- AIRSUPRA$125
- Wegovy$125
- SOLIRIS$125
- CAMZYOS$113
- ULTOMIRIS$113
- Saxenda$113
- XARELTO$106
How this compares
$14,996 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $108,854 |
| EliquisApixaban | 84 | $91,333 |
| MounjaroTirzepatide | 37 | $41,675 |
| TrulicityDulaglutide | 24 | $39,157 |
| OzempicSemaglutide | 26 | $35,535 |
| JanuviaSitagliptin Phosphate | 30 | $34,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $32,531 |
| TradjentaLinagliptin | 31 | $32,420 |
| FarxigaDapagliflozin Propanediol | 29 | $24,597 |
| EntrestoSacubitril/Valsartan | 13 | $11,220 |
| XareltoRivaroxaban | 21 | $10,680 |
| MyrbetriqMirabegron | 18 | $10,554 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,695 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $7,341 |
| InvokametCanagliflozin/Metformin Hcl | 12 | $6,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $112 | $141,274118 claims |
| PfizerEliquis | $382 | $91,33384 claims |
| Lilly USA, LLCMounjaro, Trulicity | $657 | $80,83261 claims |
| Novo NordiskOzempic | $590 | $35,53526 claims |
| MerckJanuvia | $143 | $34,59030 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $994 | $34,29240 claims |
| GSKTrelegy Ellipta | $180 | $32,53142 claims |
| Johnson & JohnsonXarelto, Invokamet | $195 | $17,51533 claims |
| NovartisEntresto | $33 | $11,22013 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $10,55418 claims |
| AbbVieSynthroid | $1,410 | $1,18223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Johnstown
- Christy JamesJohnstown$16K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.